Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q1 2026
Biocryst Pharmaceuticals (BCRX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Biocryst Pharmaceuticals (BCRX) reported revenue of $156M for the first quarter 2026 (Q1 2026), +7% from a year earlier and -62% from the quarter before. Operating margin was -448.6%, net loss $722M (461.5% of revenue).
Biocryst Pharmaceuticals, Q1 2026: revenue $156M (+8% year over year), operating margin -448.6%, net loss $722M, operating cash flow −$61.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $156M | -62% | +7% |
| Operating profit | −$702M | -369% | -3405% |
| Net earnings | −$722M | -394% | -2255762% |
| Operating cash flow | −$61.8M | -121% | — |
What changed
Revenue was $156.4M in Q1 2026, up 7% year over year and down 62% from the previous quarter. ORLADEYO was the largest line at 95% of revenue. ORLADEYO added $14.1M year over year (up 11%), 130% of the total change. Other revenues declined 55%.
Operating costs exceeded revenue by $701.6M, an operating margin of -448.6%. Total costs grew 590% against revenue growth of 7%. The fastest-growing cost line was Research & development (+62%). The quarter ended with a net loss of $721.8M, after a profit of $245.8M the previous quarter.
Operating cash flow was −$61.8M. Non-cash charges added back $1.1M of depreciation and amortization and $16.0M of share-based compensation. Working capital and other items added $642.9M. Capital expenditures of $403K exceeded it, leaving free cash flow of −$62.2M.
Questions
What was Biocryst Pharmaceuticals' revenue in the first quarter 2026?
Biocryst Pharmaceuticals (BCRX) reported revenue of $156M for the first quarter 2026 (Q1 2026), +7% from a year earlier and -62% from the quarter before.
Was Biocryst Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $702M (-448.6% of revenue) and net loss $722M.